Search

Author/Creator Lo Russo, G.

1. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils. (December 2022)

Authors:
Ferrara, R.; Lo Russo, G.; Ciniselli, C.M.; Bassani, B.; Calareso, G.; Duroni, V.; Di Gregorio, S.; Proto, C.; Prelaj, A.; De Toma, A.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Mazzeo, L.; Ganzinelli, M.; De Braud, F.G.M.; Garassino, M.C.; Colombo, M.P.; Verderio, P.; Sangaletti, S.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results. (December 2022)

Authors:
Peters, S.; Lim, S.M.; Ortega Granados, A.L.O.; Pinto, G.D.J.; Fuentes, C.S.; Lo Russo, G.; Schenker, M.; Ahn, J.S.; Reck, M.; Szijgyarto, Z.; Huseinovic, N.; Zografos, E.; O'Donnell, S.; de Marinis, F.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (May 2019)

Authors:
Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L.M.; De Simone, I.; Colombo, M.P.; Sica, A.; Torri, V.; Garassino, M.C.
Journal:
Cancer treatment reviews
Issue:
Volume 75(2019)
Page Start:
39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search